По вашему запросу найдено документов: 908

Страница 1 из 91

EFFICACY OF ONCE-WEEKLY ADMINISTRATION OF CTP-MODIFIED HUMAN GROWTH HORMONE (MOD-4023): 24-MONTH COMPLETE DATABASE RESULTS OF A PHASE 2 STUDY IN CHILDREN WITH GROWTH HORMONE DEFICIENCY
Zelinska, N., Skorodok, J., Skorodok, J., Malievsky, O., Rosenfeld, R.G., Zadik, Z., Koren, R., Vander, S., Hart, G., Raduk, D. (2016)
utilizing a technology called CTP.
SAFETY AND TOLERABILITY OF ONCE-WEEKLY ADMINISTRATION OF CTP-MODIFIED HUMAN GROWTH HORMONE (MOD-4023): 24-MONTH COMPLETE DATASET RESULTS OF A PHASE 2 STUDY IN CHILDREN WITH GROWTH HORMONE DEFICIENCY
Zelinska, N., Skorodokb, J., Malievsky, O., Rosenfeldd, Ron G., Zadike, Zvi, Korenf, R., Vanderf, Sh., Hartf, G., Radziukg, K. (2016)
human GH (hGH) developed for once-weekly administration in growth hormone deficient (GHD) adults
A HYBRID FC-FUSED HUMAN GROWTH HORMONE, GX-H9, SHOWS A POTENTIAL FOR WEEKLY AND TWICE-MONTHLY ADMINISTRATION IN CHILDREN WITH GROWTH HORMONE DEFICIENCY
Mykola, A., Malievskiy, O, Nataliya, Z, Bolshova, EV, Senatorova, G, Oroszlan, G, Skorodok, J, Peterkova, V, Nataliya, C, Sorokman, T, Yang, S, Lee, JE, Muzsnai, A, Hwang, JS, Kim, T, Choi, YJ, Woo, J, Jang, WI, Sung, YC, Keyoung, M (2017)
A HYBRID FC-FUSED HUMAN GROWTH HORMONE, GX-H9, SHOWS A POTENTIAL FOR WEEKLY AND TWICE
Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study
Deal, C, Steelman, J, Vlachopapadopoulou, E, Stawerska, R, Silverman, LA;, Phillip, M, Kim, HS, Ko, CW, Malievskiy, O, Cara, JF, Roland, CL, Taylor, CT, Valluri, SR, Wajnrajch, MP, Pastrak, A, Miller, BS (2022)
Context: Somatrogon is a long-acting recombinant human growth hormone (rhGH) in development
An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment
Zadik, Zvi, Zelinska, Nataliya, Iotova, Violeta, Skorodok, Yulia, Malievsky, Oleg, Mauras, Nelly, Valluri, Srinivas Rao, Pastrak, Aleksandra, Rosenfeld, Ron (2023)
Objectives: Somatrogon is a long-acting recombinant human growth hormone (GH) employed as a once
Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results
Maniatis, AK;, Casella, SJ;, Nadgir, UM;, Hofman, PL;, Saenger, P;, Chertock, ED;, Aghajanova, EM;, Korpal-Szczyrska, M;, Vlachopapadopoulou, E;, Malievskiy, O;, Chaychenko, T;, Cappa, M;, Song, WJ;, Mao, M;, Mygind, PH;, Smith, AR;, Chessler, S;, Komirenko, AS;, Beckert, M;, Aimee, D Shu, Paul, S Thornton (2022)
the long-term safety and efficacy of weekly administered long-acting growth hormone lonapegsomatropin
LONG-ACTING C-TERMINAL PEPTIDE-MODIFIED HGH (MOD-4023): RESULTS OF A SAFETY AND DOSE-FINDING STUDY IN GHD CHILDREN
Zelinska, N., Iotova, V., Skorodok, J., Malievsky, O., Peterkova, V., Samsonova, L., Rosenfeld, Ron G., Zadik, Zvi, Jaron-Mendelson, Michal, Koren, Ronit, Amitzi, Leanne, Raduk, Dmitri, Hershkovitz, Oren, Hart, Gili (2017)
Context: Daily injections are required for growth hormone (GH) replacement therapy, which may cause
Comparing the efficacy and safety of weekly somatrogon with daily somatropin to treat children with growth hormone deficiency: a plain language summary of publication
Deal, Cheri L., Steelman, Joel, Vlachopapadopoulou, Elpis, Stawerska, Renata, Silverman, Lawrence A., Phillip, Moshe, Kim, Ho-Seong, Ko, CheolWoo, Malievskiy, Oleg, Cara, Jose F., Roland, Carl L., Taylor, Carrie Turich, Valluri, Srinivas Rao, Wajnrajch, Michael P., Pastrak, Aleksandra, Miller, Bradley S. (2024)
injections to treat children who don’t make enough growth hormone to grow adequately. ○ Efficacy refers
Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results
Maniatis, Aristides K., Thornton, Paul S., Nadgir, Ulhas M., Vlachopapadopoulou, Elpis, Malievskiy, Oleg, Aghajanova, Elena M., Korpal-Szczyrska, Maria, Woods, Katie A., Mao, Meng, Zhao, Carol, Abdelrahman, Sohair G., Huang, Eric A., Komirenko, Allison S., Shu, Aimee D., Shu, A.D., Hofman, Paul (2025)
-term safety and efficacy of once-weekly lonapegsomatropin in children with growth hormone deficiency (GHD
12-Month Effects of Once-Weekly and Twice-Monthly Administration of Hybrid Fc-Fused Human Growth Hormone, GX-H9, Treatment in Pediatric with GHD Deficiency
Malieyskiy, O., Mykola, A., Nataliya, Z., Bolshova, E.V., Senatorova, G., Oroszlan, G., Skorodok, J., Peterkova, V., Nataliya, C., Sorokman, T., Yang, S., Lee, J.E., Muzsnai, A., Hwang, J.S., Lee, S.Y., Choi, Y.J., Ji, H.J., Woo, J., Sung, Y.C. (2018)
GX-H9 is a long-acting form of recombinant human GH under clinical development for both adults

Страница 1 из 91

Google Scholar
OpenDoar

Фасеты

Научный руководитель
Авторы
Ключевые слова
Год